Navigation Links
Thomas Jefferson University receives Science Center's QED Award for pancreatic cancer research
Date:12/13/2011

PHILADELPHIAHwyda Arafat, M.D., Ph.D., Associate Professor of Surgery at Thomas Jefferson University and co-director of the Jefferson Pancreatic, Biliary and Related Cancers Center, and Mon-Li Chu, Ph.D., Professor and Vice Chair of the Department of Dermatology and Cutaneous Biology, were awarded $200,000 from the University City Science Center's QED Proof of Concept Program for their breakthrough work on a diagnostic test for pancreatic cancer.

Developed at Jefferson, it is poised to be the first clinically reliable test for pancreatic ductal adenocarcinoma (PDA), the primary form of pancreatic cancer, which currently has no reliable system for early detection.

This is the first time Thomas Jefferson University has received a QED award, which stands for Quod Erat Demonstrandum or "proven as demonstrated." Drs. Arafat and Chu's project was one of three to be selected to receive funding awards in Round 4.

The QED Program is designed to facilitate commercial investment in early-stage life science technologies with high potential in the healthcare industry. Awards are made to bridge the funding gap between research grants and commercial seed investment by awarding grants to life science technologies with high potential in the healthcare industry.

"As a longstanding supporter of the QED Program, Jefferson is truly excited to receive its first funding award," said Steven McKenzie, M.D., Ph.D., Professor of Medicine and Pediatrics, and Vice President for Research at Thomas Jefferson University. "The QED program offers a unique chance for research faculty to engage in product-oriented research guided by entrepreneurs, investors, and companies. These opportunities are a big part of the momentum we're seeing in technology commercialization in our region."

In addition to the $200,000 award, each research team receives one year of business guidance from the Science Center's network of experienced entrepreneurs to help them bring their technologies to market.

The projects were selected from 10 finalists by an independent group comprised of industry and investment professionals. The Jefferson team is receiving input from QED Business Advisors Chris Blaxland, Dave Hesson and Don Skerrett.

"It's an honor to be recognized by the Science Center with this award," said Dr. Arafat. "Given the outcome for so many pancreatic cancer patients, it's imperative we find better tools to detect this deadly cancer earlier. This funding will help me and my Jefferson colleagues to further develop our research and apply it to a diagnostic product that could potentially be used to help save lives."

PDA is the fourth leading cause of cancer death in the United States and worldwide, with the number of diagnosed cases virtually equaling the number of deaths. Currently, there is no diagnostic marker for PDA. Based upon data showing higher levels of COL6A3 protein in PDA patients, Jefferson's Proof‐of‐Concept Plan is proposing to conduct a study with a larger patient cohort to develop new antibodies that could be used for a diagnostic assay.

A reliable diagnostic for PDA is expected to save lives through early intervention, and to have economic benefits by reducing unneeded surgeries, laparoscopic biopsies and wrong diagnoses.

"The funding and the recognition of the QED award are critical for moving our technology from the lab to potential commercialization," said Dr. Chu. "This award would not have been possible without the continuous support from the Office of Technology Transfer."


'/>"/>

Contact: Steve Graff
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Thomas Jefferson University Hospital cuts Whipple procedure wound infections in half with new measures
2. Thomas Jefferson University Hospital adopts new imaging agent to improve detection of bladder cancer
3. Thomas Jefferson University and hospitals tasked to find new radiation drugs
4. Thomas Kipps receives ACGT Investigator Award
5. Thomas Jefferson University professor elected AAAS Fellow
6. Gala honors County Supervisor Mark Ridley-Thomas and businesswoman Anne-Merelie Murrell
7. Nationally Renowned Knee Specialist Dr. Thomas Meade Joins Coordinated Health
8. Thomas E. Heftler Migraine Research Award
9. Life Coach and Author Thomas Finn's Highly Anticipated Book, 'A Better Tomorrow- Affirmations and Visualizations the Keys to Success,' Debuts June 15
10. Thomas E. Mower Makes Generous Donations To Primary Children's Medical Center
11. Thomas E. Mower And Karl Malone Instrumental To Success Of Sportsmen For Fish And Wildlife Organization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... St. Petersburg, Florida (PRWEB) , ... January 17, 2017 , ... ... and the Producers of AsSeenOnTV.pro will be featuring DRTV campaigns regarding the topic of ... year to become a better version of themselves. What better way to commit to ...
(Date:1/17/2017)... TX (PRWEB) , ... January 17, 2017 , ... Mirror ... have earned the highest honor of Diamond Level in Zeltiq’s Crystal Rewards Program. Practice ... named part of this elite group of providers. , Produced by Zeltiq, CoolSculpting ...
(Date:1/17/2017)... ... January 17, 2017 , ... A prescription medication bottle, pocket knife, luggage ... Cradle to Cradle Product Design Challenge , the Cradle to Cradle Products Innovation ... circular design challenges scheduled to run through early 2018. The challenges are presented by ...
(Date:1/17/2017)... ... January 17, 2017 , ... SC&H Group, a leading audit, ... Principal in its IT Advisory Services practice . Rossi is the third technology ... demand for strategic IT guidance grows, and the practice continues to expand.     , Bringing ...
(Date:1/17/2017)... ... January 17, 2017 , ... The Sharie ... Tyler, has announced the latest beneficiary of their thriving community involvement program. The ... dedicated to fulfilling the dreams of terminally ill patients. Donations to this worthy ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... ReportsnReports.com adds "Anaphylaxis - Pipeline Review, H2 2016" ... Anaphylaxis,s therapeutic pipeline with comprehensive information on the therapeutic development ... assessment by drug target, mechanism of action (MoA), route of ... featured news and press releases. ... Complete report on H2 2016 pipeline ...
(Date:1/17/2017)... 2017 Immune Pharmaceuticals (NASDAQ: IMNP ... that it will hold a Satellite Symposium on February 20th, ... XVI in Munich, Germany . ... of Immunotherapy for the maintenance of remission in AML ... th , 2017 from 12:45 – 13:45 CET in ...
(Date:1/17/2017)... Research and Markets has announced the addition of the "Global ... ... market to grow at a CAGR of 7.94% during the period ... been prepared based on an in-depth market analysis with inputs from ... prospects over the coming years. The report also includes a discussion ...
Breaking Medicine Technology: